Kura Oncology reveals first results in AML combination therapy at upcoming conference

Kura Oncology reveals first results in AML combination therapy at upcoming conference
Kura Oncology to share AML data

Kura Oncology announced it will present several abstracts at the 68th American Society of Hematology (ASH) Annual Meeting. The company, in collaboration with Kyowa Kirin, will unveil new clinical data on combination treatment approaches for acute myeloid leukemia, including the first reported results from these studies.

This presentation aims to share progress in developing novel therapies for AML, reflecting an emphasis on research collaboration and clinical innovation.

Kura Oncology previously announced plans to present new clinical data on AML combination treatments with Kyowa Kirin at the 68th ASH Annual Meeting, according to a recent report. Earlier, the company began enrolling patients in the FIT-001 Phase 1b trial, which tests an investigational therapy for advanced renal cell carcinoma as noted in a prior update. These developments highlight Kura's ongoing clinical research activity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.